Drugs / BBO-8520
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06343402 | May 2024 → Apr 2031 expected | non-small cell lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBO-8520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06343402 ↗ |
| Action | Inhibit | “a KRAS G12C (ON and OFF) inhibitor” NCT06343402 ↗ |
| Route | Oral | “Participants will receive assigned dose of BBO-8520 orally (PO), QD” NCT06343402 ↗ |
| Target | KRAS | “a KRAS G12C (ON and OFF) inhibitor” NCT06343402 ↗ |